GNLX
GENELUX Corp
Key Financials
Operating Income
$-33214000
↓ 4.8%
Net Income
$-32145000
↓ 7.6%
Revenue
$8000
0.0%
Total Liabilities
$7.5M
↓ 11.4%
EPS (Diluted)
$-0.86
↑ 9.5%
Shareholders' Equity
$11.5M
↓ 56.1%
Cash & Equivalents
$5.3M
↓ 37.7%
Total Assets
$19.0M
↓ 45.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/4/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 144 | 6/1/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| 4 | 5/12/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| ARS | 4/29/2026 | View on SEC |
| DEFA14A | 4/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GNLX |
| Company Name | GENELUX Corp |
| CIK | 1231457 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 805-267-9889 |